Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Abstract LB365: Results from a phase 1 study of botensilimab and balstilimab in treatment refractory hepatocellular carcinoma

Anthony B. El-Khoueiry, MD, Ghassan K. Abou-Alfa, MD, PhD, JD, MBA, Breelyn A. Wilky, MD, Apostolia M. Tsimberidou, MD, PhD, Daruka Mahadevan, MD, PhD, Diana L. Hanna, MD, Bruno Bockorny, MD, Daniel E. Fein, MD, Christopher H. Lieu, MD, Alexis Leal, MD, Cara Constance, PhD, BSN, Manushak Avagyan, MD, MPH, Wei Wu, MS, Joseph E. Grossman, MD, Benny Johnson, DO, Andrea J. Bullock, MD

Cancer Res (2025) 85 (8_Supplement_2): LB365.

https://doi.org/10.1158/1538-7445.AM2025-LB365

Published: 25 April 2025

View articletitled, Abstract LB365: Results from a phase 1 study of botensilimab and balstilimab in treatment refractory hepatocellular carcinoma

Journal Articles

Abstract 5510: Targeting BET, Hippo-YAP and RAS-MAPK signaling interplay in lung cancer and therapy resistance

Nilanjana Chatterjee, Victor Olivas, Wei Wu, Tracy Tang, Ben Powell, Trever Bivona

Cancer Res (2025) 85 (8_Supplement_1): 5510.

https://doi.org/10.1158/1538-7445.AM2025-5510

Published: 21 April 2025

View articletitled, Abstract 5510: Targeting BET, Hippo-YAP and RAS-MAPK signaling interplay in lung cancer and therapy resistance

Journal Articles

Abstract 6389: Unveiling the potent anti-tumor activity and underlying mechanism of action of the novel pan-RAF inhibitor exarafenib in BRAF-mutated NSCLC

Cancer Res (2025) 85 (8_Supplement_1): 6389.

https://doi.org/10.1158/1538-7445.AM2025-6389

Published: 21 April 2025

View articletitled, Abstract 6389: Unveiling the potent anti-tumor activity and underlying mechanism of action of the novel pan-RAF inhibitor exarafenib in BRAF-mutated NSCLC

Journal Articles

Abstract 5329: Development of a novel selective CDK4 inhibitor for HR+/HER2- breast cancer

Cancer Res (2025) 85 (8_Supplement_1): 5329.

https://doi.org/10.1158/1538-7445.AM2025-5329

Published: 21 April 2025

View articletitled, Abstract 5329: Development of a novel selective CDK4 inhibitor for HR+/HER2- breast cancer

Journal Articles

Abstract 5338: TY-1781, a potent and highly selective CDK2 inhibitor, demonstrates superior anti-tumor activity in CCNE1 high-expression solid tumor models

Chengshan Niu, Meihua Li, Shaoqing Chen, Maolin Zheng, Mingtao Chen, Hui Xu, Kaige Ji, Yuanjie Li, Rui Wu, Shengli Dong, Yu Yu, Xinlong Yang, Chao Zhou, Apeng Liang, Wei Wu, Mingyu Jiang, Jun Li, Yusheng Wu

Cancer Res (2025) 85 (8_Supplement_1): 5338.

https://doi.org/10.1158/1538-7445.AM2025-5338

Published: 21 April 2025

View articletitled, Abstract 5338: TY-1781, a potent and highly selective CDK2 inhibitor, demonstrates superior anti-tumor activity in CCNE1 high-expression solid tumor models

Journal Articles

Abstract 5557: Deciphering the interplay of β-catenin/YAP signaling and alveolar lineage plasticity during targeted therapy in non-small cell lung cancer

Yu-Ting Chou, Wei Wu, D. Lucas Kerr, Victor Olivas, Macey Slota, Trever G. Bivona

Cancer Res (2025) 85 (8_Supplement_1): 5557.

https://doi.org/10.1158/1538-7445.AM2025-5557

Published: 21 April 2025

View articletitled, Abstract 5557: Deciphering the interplay of β-catenin/YAP signaling and alveolar lineage plasticity during targeted therapy in non-small cell lung cancer

Journal Articles

Abstract 2600: A human stem cell model of neuroblastoma reveals candidate drivers of tumorigenesis on chromosome 17q

Wanqi Fang, Bo Cheng, Steven J. Pastor, Ivana Barbaric, Anestis Tsakiridis, Tania Porras, Hong-Wei Wu, Chintan Parekh, Shahab Asgharzadeh, John M. Maris, Miller Huang

Cancer Res (2025) 85 (8_Supplement_1): 2600.

https://doi.org/10.1158/1538-7445.AM2025-2600

Published: 21 April 2025

View articletitled, Abstract 2600: A human stem cell model of neuroblastoma reveals candidate drivers of tumorigenesis on chromosome 17q

Journal Articles

Abstract 4480: Novel targeting API@API nanomedicines for synergistic molecular signaling modulation in head and neck cancer and the microenvironment

Li-Xing Yang, Ru-Fen Chen, Yan-Wei Wu, Pei-Wen Wang, Chih-Chia Huang, Dar-Bin Shieh

Cancer Res (2025) 85 (8_Supplement_1): 4480.

https://doi.org/10.1158/1538-7445.AM2025-4480

Published: 21 April 2025

View articletitled, Abstract 4480: Novel targeting API@API nanomedicines for synergistic molecular signaling modulation in head and neck cancer and the microenvironment

Journal Articles

Abstract 5977: Identification and characterization of an allosteric and mutant-selective PI3Kα inhibitor

Chengshan Niu, Shengli Dong, Shaoqing Chen, Kaige Ji, Maolin Zheng, Mingtao Chen, Yuanjie Li, Meihua Li, Zhengfei Guo, Hongqiang Li, Yu Yu, Xinlong Yang, Chao Zhou, Apeng Liang, Yin Zhou, Wei Wu, Mingyu Jiang, Jun Li, Yusheng Wu

Cancer Res (2025) 85 (8_Supplement_1): 5977.

https://doi.org/10.1158/1538-7445.AM2025-5977

Published: 21 April 2025

View articletitled, Abstract 5977: Identification and characterization of an allosteric and mutant-selective PI3Kα inhibitor

Journal Articles

Abstract 7006: TY-2719, a potent and selective broad-spectrum mutation-effective EGFR-PROTAC molecule, attenuates acquired resistance to 3^rd-generation EGFR TKIs

Apeng Liang, Shengli Dong, Shaoqing Chen, Shunxun Han, Hongqiang Li, Guangbin Liu, Xi Wang, Zhengfei Guo, Yanyan Liu, Ling Fang, Yi Long, Xiang Zhang, Wei Wu, Chengshan Niu, Mingyu Jiang, Jun Li, Yusheng Wu

Cancer Res (2025) 85 (8_Supplement_1): 7006.

https://doi.org/10.1158/1538-7445.AM2025-7006

Published: 21 April 2025

View articletitled, Abstract 7006: TY-2719, a potent and selective broad-spectrum mutation-effective EGFR-PROTAC molecule, attenuates acquired resistance to 3rd-generation EGFR TKIs

Journal Articles

Abstract C025: Identification of cell-cell signaling programs across the tumor-tumor microenvironment ecosystem and associated with clinical status in neoadjuvant osimertinib treated patient samples revealed by spatial profiling

Whitney Tamaki, Daniel L. Kerr, Wei Wu, Grant Eilers, Anatoly Urisman, Yu-Ting Chou, Philippe Gui, Shigeki Nanjo, Johannes R. Kratz, David M. Jablons, Trever G. Bivona, Collin M. Blakely

Cancer Res (2024) 84 (22_Supplement): C025.

https://doi.org/10.1158/1538-7445.TUMBODY-C025

Published: 17 November 2024

View articletitled, Abstract C025: Identification of cell-cell signaling programs across the tumor-tumor microenvironment ecosystem and associated with clinical status in neoadjuvant osimertinib treated patient samples revealed by spatial profiling

Journal Articles

Abstract LB451: Targeting oncogenic transcription and signaling crosstalk fueling drug resistance in lung cancer

Nilanjana Chatterjee, Victor Olivas, Wei Wu, Tracy Tang, Ben Powell, Trever Bivona

Cancer Res (2024) 84 (7_Supplement): LB451.

https://doi.org/10.1158/1538-7445.AM2024-LB451

Published: 05 April 2024

View articletitled, Abstract LB451: Targeting oncogenic transcription and signaling crosstalk fueling drug resistance in lung cancer

Journal Articles

Abstract 457: Persister cell state-associated lncRNA signatures in non-small cell lung cancer

Jovanka Gencel-Augusto, Wei Wu, Trever G. Bivona

Cancer Res (2024) 84 (6_Supplement): 457.

https://doi.org/10.1158/1538-7445.AM2024-457

Published: 22 March 2024

View articletitled, Abstract 457: Persister cell state-associated lncRNA signatures in non-small cell lung cancer

Journal Articles

Abstract 2006: Deciphering the interplay of β-catenin/YAP signaling and alveolar lineage plasticity during targeted therapy in non-small cell lung cancer

Yu-Ting Chou, Wei Wu, Daniel Kerr, Macey Slota, Trever Bivona

Cancer Res (2024) 84 (6_Supplement): 2006.

https://doi.org/10.1158/1538-7445.AM2024-2006

Published: 22 March 2024

View articletitled, Abstract 2006: Deciphering the interplay of β-catenin/YAP signaling and alveolar lineage plasticity during targeted therapy in non-small cell lung cancer

Journal Articles

Abstract 1057: A blood-based multi-omics test for multicancer early detection: Combined retrospective and prospective studies

Mao Mao, Shiyong Li, Qingqi Ren, Yi Luan, Weijie Liang, Shuaipeng Geng, Dao-Ling Huang, Dandan Zhu, Yinyin Chang, Wei Wu, Yingying Zhang, Linfeng Zhang, Yan Wang, Yumin Feng, Bing Wei, Jie Ma, Chaohui Duan, Guanghui Long

Cancer Res (2024) 84 (6_Supplement): 1057.

https://doi.org/10.1158/1538-7445.AM2024-1057

Published: 22 March 2024

View articletitled, Abstract 1057: A blood-based multi-omics test for multicancer early detection: Combined retrospective and prospective studies

Journal Articles

Abstract 1269: Large-scale validaton studies of a blood-based effective and affordable test for multicancer early detection

Mao Mao, Bing Wei, Qingxia Xu, Yong Shen, Raphael Brandão, Shiyong Li, Wei Wu, Pingping Xing, Yinyin Chang, Dandan Zhu

Cancer Res (2024) 84 (6_Supplement): 1269.

https://doi.org/10.1158/1538-7445.AM2024-1269

Published: 22 March 2024

View articletitled, Abstract 1269: Large-scale validaton studies of a blood-based effective and affordable test for multicancer early detection

Journal Articles

Fimepinostat Impairs NFκB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma

Dan Wang, Kun Yan, Hongxing Yu, Haocheng Li, Wei Zhou, Yaqiang Hong, Shuning Guo, Yi Wang, Cheng Xu, Changcun Pan, Yujie Tang, Nian Liu, Wei Wu, Liwei Zhang, Qiaoran Xi

Cancer Res (2024) 84 (4): 598–615.

https://doi.org/10.1158/0008-5472.CAN-23-0394

Published: 15 February 2024

View articletitled, Fimepinostat Impairs NFκB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma

Includes: Supplementary data

Journal Articles

Abstract IA016: Replication-coupled and canonical DNA double strand breaks are processed by distinct mechanisms

Raphael Pavani, Veenu Tripathi, Dali Zong, Elsa Callen, Ajith Pankajam, Andre Nussenzweig, Wei Wu, Kyle Vrtis, Raj Chari, Johannes C Walter

Cancer Res (2024) 84 (1_Supplement): IA016.

https://doi.org/10.1158/1538-7445.DNAREPAIR24-IA016

Published: 09 January 2024

View articletitled, Abstract IA016: Replication-coupled and canonical DNA double strand breaks are processed by distinct mechanisms

Journal Articles

Abstract CT141: Combination of hormone therapy, GnRH agonist, and immunotherapy enhance immune activation in premenopausal ER+/HER2- metastatic breast cancer patients: Results of biomarker analysis from a pilot phase II study

I-Chun Chen, Ching-Hung Lin, Dwan-Ying Chang, Tom Wei-Wu Chen, Ming-Yang Wang, Wei-Li Ma, Yi-Ting Lin, Shu-Min Huang, Yen-Shen Lu

Cancer Res (2023) 83 (8_Supplement): CT141.

https://doi.org/10.1158/1538-7445.AM2023-CT141

Published: 14 April 2023

View articletitled, Abstract CT141: Combination of hormone therapy, GnRH agonist, and immunotherapy enhance immune activation in premenopausal ER+/HER2- metastatic breast cancer patients: Results of biomarker analysis from a pilot phase II study

Journal Articles

Abstract 605: Single cell RNA sequencing reveals tumor immune microenvironment and T cell receptor diversity in epidermal growth factor receptor (EGFR) mutated lung cancer

Turja Chakrabarti, Wei Wu, Daniel L. Kerr, Paul Allegakoen, Trever G. Bivona, Collin M. Blakely

Cancer Res (2023) 83 (7_Supplement): 605.

https://doi.org/10.1158/1538-7445.AM2023-605

Published: 04 April 2023

View articletitled, Abstract 605: Single cell RNA sequencing reveals tumor immune microenvironment and T cell receptor diversity in epidermal growth factor receptor (EGFR) mutated lung cancer

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract LB365: Results from a phase 1 study of botensilimab and balstilimab in treatment refractory hepatocellular carcinoma

Abstract 5510: Targeting BET, Hippo-YAP and RAS-MAPK signaling interplay in lung cancer and therapy resistance

Abstract 6389: Unveiling the potent anti-tumor activity and underlying mechanism of action of the novel pan-RAF inhibitor exarafenib in BRAF-mutated NSCLC

Abstract 5329: Development of a novel selective CDK4 inhibitor for HR+/HER2- breast cancer

Abstract 5338: TY-1781, a potent and highly selective CDK2 inhibitor, demonstrates superior anti-tumor activity in CCNE1 high-expression solid tumor models

Abstract 5557: Deciphering the interplay of β-catenin/YAP signaling and alveolar lineage plasticity during targeted therapy in non-small cell lung cancer

Abstract 2600: A human stem cell model of neuroblastoma reveals candidate drivers of tumorigenesis on chromosome 17q

Abstract 4480: Novel targeting API@API nanomedicines for synergistic molecular signaling modulation in head and neck cancer and the microenvironment

Abstract 5977: Identification and characterization of an allosteric and mutant-selective PI3Kα inhibitor

Abstract 7006: TY-2719, a potent and selective broad-spectrum mutation-effective EGFR-PROTAC molecule, attenuates acquired resistance to 3^rd-generation EGFR TKIs

Abstract C025: Identification of cell-cell signaling programs across the tumor-tumor microenvironment ecosystem and associated with clinical status in neoadjuvant osimertinib treated patient samples revealed by spatial profiling

Abstract LB451: Targeting oncogenic transcription and signaling crosstalk fueling drug resistance in lung cancer

Abstract 457: Persister cell state-associated lncRNA signatures in non-small cell lung cancer

Abstract 2006: Deciphering the interplay of β-catenin/YAP signaling and alveolar lineage plasticity during targeted therapy in non-small cell lung cancer

Abstract 1057: A blood-based multi-omics test for multicancer early detection: Combined retrospective and prospective studies

Abstract 1269: Large-scale validaton studies of a blood-based effective and affordable test for multicancer early detection

Fimepinostat Impairs NFκB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma

Abstract IA016: Replication-coupled and canonical DNA double strand breaks are processed by distinct mechanisms

Abstract CT141: Combination of hormone therapy, GnRH agonist, and immunotherapy enhance immune activation in premenopausal ER+/HER2- metastatic breast cancer patients: Results of biomarker analysis from a pilot phase II study

Abstract 605: Single cell RNA sequencing reveals tumor immune microenvironment and T cell receptor diversity in epidermal growth factor receptor (EGFR) mutated lung cancer

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only